

Fax Cover Sheet

Lilly

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A.

LRL Law

RECEIVED
CENTRAL FAX CENTER

To: USPTO From: Thomas E. LaGrandeur FEB 19 2004
Eli Lilly And Company

Company: 317/ 276-5172 278-3861 **OFFICIAL**

Fax: 1-703-872-9306 Phone: (317) 651-1527

Phone: _____ Total Pages (including cover): 11

Date: February 17, 2004

RE: REPLY UNDER 37 C.F.R. 111

Charles Jack Fisher and Sau-Chi Betty Yan
Serial No. : 09/842,337
Filed : April 25, 2001
For : METHOD OF TREATING VIRAL
HEMORRHAGIC FEVER
Docket No. : X-12449A

THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE INDIVIDUAL TO WHOM IT IS ADDRESSED AND MAY
CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL OR EXEMPT FROM DISCLOSURE UNDER APPLICABLE
LAW. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE (COLLECT), AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA U.S. POSTAL
SERVICE.

If there are any problems with this transmittal, please call Candi Gaines at (317)433-1540.

Answers That Matter.™

RECEIVED
CENTRAL FAX CENTER

FEB 19 2004

OFFICIAL

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Ethel Gaines

Type or print name of person signing certification

Ethel Gaines

Signature

February 17, 2004

Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Charles Jack Fisher and Sau-Chi Betty Yan)	
Serial No.	:	09/842,337)	
Filed	:	April 25, 2001)	Group Art Unit: 1651
For	:	METHOD OF TREATING VIRAL HEMORRHAGIC FEVER)	Examiner: J. Weber
Docket No.	:	X-12449A)	

REPLY UNDER 37 C.F.R. 111

- Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Introductory Comments

In response to the Office Action dated December 15, 2003. Applicants submit the accompanying remarks.

Remarks begin on page 2 of this paper.

Attachments: Gerson *et al.*, Pediatrics 91:418-422, 1993 (Cite No. CI on PTO Form 1449 submitted October 14, 2003) and EMEA CEPROTIN Abstract (Cite No. CL on PTO Form 1449 submitted October 14, 2003).